Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - PPHLN1 BRAF V600E |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - PPHLN1 BRAF V600E | intrahepatic cholangiocarcinoma | predicted - resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of BRAF V600E in an intrahepatic cholangiocarcinoma cell line harboring FGFR2-PPHLN1 conferred resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 33709535). | 33709535 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|